<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">39030</article-id><article-id pub-id-type="doi">10.7554/eLife.39030</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-116026"><name><surname>Zeng</surname><given-names>Mei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116027"><name><surname>Kwiatkowski</surname><given-names>Nicholas P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-83473"><name><surname>Zhang</surname><given-names>Tinghu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-83482"><name><surname>Nabet</surname><given-names>Behnam</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6738-4200</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116028"><name><surname>Xu</surname><given-names>Mousheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116029"><name><surname>Liang</surname><given-names>Yanke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116030"><name><surname>Quan</surname><given-names>Chunshan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78748"><name><surname>Wang</surname><given-names>Jinhua</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116031"><name><surname>Hao</surname><given-names>Mingfeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116032"><name><surname>Palakurthi</surname><given-names>Sangeetha</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116033"><name><surname>Zhou</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116034"><name><surname>Zeng</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116035"><name><surname>Kirschmeier</surname><given-names>Paul T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116036"><name><surname>Meghani</surname><given-names>Khyati</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124225"><name><surname>Leggett</surname><given-names>Alan L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104530"><name><surname>Qi</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124226"><name><surname>Shapiro</surname><given-names>Geoffrey I</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124227"><name><surname>Liu</surname><given-names>Joyce F</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116037"><name><surname>Matulonis</surname><given-names>Ursula A</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-108154"><name><surname>Lin</surname><given-names>Charles Y</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9155-090X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-11209"><name><surname>Konstantinopoulos</surname><given-names>Panagiotis A</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4531"><name><surname>Gray</surname><given-names>Nathanael S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5354-7403</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Belfer Institute for Applied Cancer Science</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Radiation Oncology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Early Drug Development Center</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Medical Oncology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Molecular and Human Genetics</institution>, <institution>Baylor College of Medicine</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-5101"><name><surname>Levine</surname><given-names>Ross L</given-names></name><role>Reviewing editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Charles.Y.Lin@bcm.edu</email> (CL);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>Panagiotis_Konstantinopoulos@DFCI.HARVARD.EDU</email> (PK);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>nathanael_gray@dfci.harvard.edu</email> (NG);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>11</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e39030</elocation-id><history><date date-type="received"><day>08</day><month>06</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Zeng et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Zeng et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-39030-v1.pdf"/><abstract><p>High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of <italic>MYC</italic> oncogene occurs in nearly half of tumors. We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating MYC as a therapeutic target for this difficult-to-treat malignancy. However, targeting MYC directly has proven difficult. We screen small molecules targeting transcriptional and epigenetic regulation, and find that THZ1 - a chemical inhibiting CDK7, CDK12, and CDK13 - markedly downregulates MYC. Notably, abolishing MYC expression cannot be achieved by targeting CDK7 alone, but require the combined inhibition of CDK7, CDK12, and CDK13. In 11 patient derived xenografts models derived from heavily pre-treated ovarian cancer patients, administration of THZ1 induces significant tumor growth inhibition with concurrent abrogation of MYC expression. Our study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>NIH R01 CA197336-02</award-id><principal-award-recipient><name><surname>Gray</surname><given-names>Nathanael S</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>NIH R01 CA179483-02</award-id><principal-award-recipient><name><surname>Gray</surname><given-names>Nathanael S</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-14-OCRP-OCACAOC140632 award</award-id><principal-award-recipient><name><surname>Konstantinopoulos</surname><given-names>Panagiotis A</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Cancer Prevention Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RR150093</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Charles Y</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA215452-01</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Charles Y</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship PF-17-010-01-CDD</award-id><principal-award-recipient><name><surname>Nabet</surname><given-names>Behnam</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Nicholas P Kwiatkowski, is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf3"><p>Tinghu Zhang, is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf4"><p>Charles Y Lin, is a consultant of Jnana Therapeutics and is a shareholder and inventor of IP licensed to Syros Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf5"><p>Nathanael S Gray, is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals.Is a scientific founder and equity holder of Syros Pharmaceuticals, C4 Therapeutics, Petra Pharma, Gatekeeper Pharmaceuticals, and Soltego.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were conducted in accordance with the animal use guidelines from the NIH and with protocols (Protocol # 11-044) approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. Full details are described in Materials and Methods - Animal Studies.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>RNA sequencing data have been deposited in GEO under accession code GSE116282.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Zeng M</collab><collab>Xu M</collab><collab>Gray NS</collab></person-group><year iso-8601-date="2018">2018</year><source>RNA sequencing data from</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116282">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116282</ext-link><comment>Gene Expression Omnibus, GSE116282</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-39030-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>